JW Pharmaceutical Secures Exclusive Rights to Develop and Market Linzagolix in South Korea

On June 11, JW Pharmaceutical announced that it has signed an exclusive license-in agreement with Japan's Kissei Pharmaceutical to develop and sell the uterine fibroid treatment 'Linzagolix' in South Korea.Through this agreement, JW Pharmaceutical secures exclusive rights to develop, man

featured-image

On June 11, JW Pharmaceutical announced that it has signed an exclusive license-in agreement with Japan's Kissei Pharmaceutical to develop and sell the uterine fibroid treatment 'Linzagolix' in South Korea. Through this agreement, JW Pharmaceutical secures exclusive rights to develop, manufacture, market, and distribute Linzagolix within South Korea. Linzagolix is a novel GnRH (gonadotropin-releasing hormone) antagonist developed by Kissei Pharmaceutical.

Taken once daily, it effectively alleviates symptoms such as heavy menstrual bleeding caused by uterine fibroids by inhibiting the production of the female hormone estrogen. In clinical phase 3 trials conducted in the U.S.



and Europe, Linzagolix demonstrated efficacy in both groups, with or without additional hormone replacement therapy (ABT). The drug received marketing approval in Europe in June 2022. Uterine fibroids are benign tumors that develop in the smooth muscle tissue of the uterus and affect approximately 40% of women over the age of 35.

While there are existing GnRH agonist treatments for uterine fibroids in South Korea, these can cause side effects such as hot flashes and injection site pain due to increased hormone levels at the start of treatment. The company expects that Linzagolix will improve the quality of life for patients with uterine fibroids in South Korea by offering immediate suppression of estrogen secretion, thus reducing early treatment side effects compared to existing GnRH agonists. Additionally.